RESTON, Va., June 1, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a global science and technology company, has been included on the annual Healthcare Informatics 100 list. This feature is a compilation of the top health IT companies based on health IT revenues from the most recent fiscal year.
Leidos, which ranked nine on the list, provides services and solutions to commercial and government clients in information technology, biomedical research, and public health. From conducting groundbreaking research to fight diseases such as cancer and AIDS, to implementing and optimizing electronic health records, Leidos provides solutions focused on improving patient care and reducing cost. The company provides a broad range of capabilities for hospitals and health systems and also develops and supports large-scale technology programs for every U.S. federal agency focused on health, including the Department of Defense, Veterans Affairs, and Health and Human Services.
"Our brilliant scientists and technical experts use their vast experience to keep us on the forefront of healthcare technology so we can devise the most innovative solutions for our customers," said Leidos Health President Jon Scholl. "Our presence on this list emphasizes the importance of the work we do, not only for the company, but to improve the health of people around the world."
Leidos is a global science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.